SCHEMBL6843949

SCHEMBL6843949

N#Cc1cccc(CSc2nccn2-c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 7/20 0.52
ALOX15B O15296 3/20 0.52
CYP1A2 P05177 4/20 0.42
CYP3A4 P08684 4/20 0.42
CYP2D6 P10635 4/20 0.42
CYP2C9 P11712 4/20 0.42
CYP2C19 P33261 4/20 0.42
GAA P10253 1/20 0.42
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
RORC P51449 1/20 0.39
NR1H3 Q13133 1/20 0.38
MRGPRX4 Q96LA9 1/20 0.38
MAPT P10636 1/20 0.38
GSK3B P49841 2/20 0.37
GSK3A P49840 1/20 0.37
CDC7 O00311 1/20 0.37
DBF4 Q9UBU7 1/20 0.37
MLYCD O95822 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14172954 0.81 L3MBTL1 (0.57) L3MBTL1ALOX15BCYP1A2CYP3A4CYP2D6
SCHEMBL2945129 0.79 MEN1 (0.53) L3MBTL1RORCNR1H3MRGPRX4MAPT
SCHEMBL24944902 0.69 L3MBTL1 (1.00) L3MBTL1ALOX15BCYP1A2CYP3A4CYP2D6
SCHEMBL24944939 0.68 CYP1A2 (0.59) L3MBTL1ALOX15BCYP1A2CYP3A4CYP2D6
SCHEMBL24945041 0.67 L3MBTL1 (0.77) L3MBTL1ALOX15BCYP1A2CYP3A4CYP2D6
SCHEMBL24945136 0.67 L3MBTL1 (0.65) L3MBTL1ALOX15BCYP1A2CYP3A4CYP2D6
SCHEMBL24944865 0.66 L3MBTL1 (0.48) L3MBTL1ALOX15BCYP1A2CYP3A4CYP2D6
SCHEMBL9431436 0.63 POLB (0.56) L3MBTL1ALOX15BCYP1A2CYP3A4CYP2D6
SCHEMBL12225979 0.63 NPC1 (0.42) L3MBTL1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL5697547 0.62 DAO (0.46) L3MBTL1MRGPRX4MAPTGSK3BGSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040087627-A1 Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2004-05-06 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087627-A1 Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors ME2, PC, ACACA L3MBTL1 1071/4885ALOX15B 565/4885CYP1A2 1233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.